How can we, humans, look at our relationship to nature differently? In season three of Going Wild, on top of stories about animals, we invite you to journey through the entire ecological web — from the tiniest of life forms to apex predators — alongside the scientists, activists and adventurers who study it. Wildlife biologist and host Dr. Rae Wynn-Grant has been studying wild animals in their natural habitats all over the world for years. Our award-winning podcast takes you inside the hidde ...
…
continue reading
Jon Chee에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 Jon Chee 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.
Player FM -팟 캐스트 앱
Player FM 앱으로 오프라인으로 전환하세요!
Player FM 앱으로 오프라인으로 전환하세요!
🧬 Terry Lo - Vizgen - Part 2 | Terry’s Move from Big Pharma to Diagnostics | Introduction to Spatial Biology | Navigating Regulatory & Reimbursement Challenges in Diagnostics | Balancing Multiple Roles in M&A Negotiations
Manage episode 411740915 series 3461709
Jon Chee에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 Jon Chee 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.
Part 2 of 3.
As a podcast listener, you can redeem exclusive discounts with a growing list of biotech vendors and get $500 off your first equipment lease by using promo code “TBSP” on https://www.excedr.com/rewards.
As a podcast listener, you can redeem exclusive discounts with a growing list of biotech vendors and get $500 off your first equipment lease by using promo code “TBSP” on https://www.excedr.com/rewards.
My guest for this week’s episode is Terry Lo, President and CEO of Vizgen. Vizgen is developing and commercializing the next generation of genomics tools to expand on the capabilities of spatially resolved transcriptomics.
Terry is a pioneer in the emerging Spatial Biology market, with a proven track record of driving exceptional growth across global life science organizations, including Bristol-Myers Squibb, Roche, Hologic, and PerkinElmer. In addition to his two decades of experience scaling and building multinational biopharma and diagnostic groups, he is also an expert in developing business strategies for novel, innovative products.
Join us for part 2 of our conversation with Terry, where we talk about his transition from Big Pharma to diagnostics, the challenges of moving into the diagnostics industry, and the contrasts between drug and diagnostic development processes. Terry also discusses his experience at Roche, his time with Akoya Biosciences after PerkinElmer, and his involvement in the M&A process while balancing multiple roles. Please enjoy my conversation with Terry Lo.
Find Our Guest, Terry Lo, at these links:
Find Our Guest, Terry Lo, at these links:
Find Our Host, Jon Chee, at these links:
Timestamps:
00:28 Intro
01:35 Leaving Bristol, joining Cytyc, and transitioning into International Strategy role
03:48 The contrasts between Diagnostics and Big Pharma
05:28 Drug development vs. diagnostics development processes
09:27 Moving to China and adapting to his role change from International Strategy to Managing Director
10:43 Adjusting to life in China with his pregnant wife
13:25 Moving back to the US and joining Roche Molecular in California
15:26 Transitioning to PerkinElmer and Terry’s intro to spatial biology
17:28 The challenges and triumphs in this new field
20:25 The challenges of regulatory agencies and reimbursement in Diagnostics and getting a product through the FDA
24:58 Merging with Akoya Biosciences after PerkinElmer to support Terry’s platform
26:51 Terry’s experience with M&A of Akoya by PerkinElmer, balancing multiple roles
29:13 Outro
Social & Website:
LinkedIn: https://www.linkedin.com/company/excedr/
Youtube: https://www.youtube.com/@excedr
Instagram: https://www.instagram.com/excedr_inc
Twitter: https://twitter.com/ExcedrInc
Facebook: https://www.facebook.com/excedr
TikTok: https://www.tiktok.com/@excedr
Podcast Website: https://www.thebiotechstartupspodcast.com/
Topics Mentioned:
Corporate Business Development https://www.rontar.com/blog/corporate-development-vs-business-development/
International Strategy https://phrase.com/blog/posts/international-strategy/
Diagnostics vs. Pharmaceuticals https://tarikyildirim.com/blog/2019/1/21/pharma-vs-diagnostics
P&L statement https://www.investopedia.com/terms/p/plstatement.asp
Drug development vs. diagnostics development https://www.ncbi.nlm.nih.gov/books/NBK235489/
AI/ML in drug development https://www.fda.gov/science-research/science-and-research-special-topics/artificial-intelligence-and-machine-learning-aiml-drug-development
Protein folding https://en.wikipedia.org/wiki/Protein_folding
Protein therapeutics https://www.nature.com/articles/nrd2399
How Biotech & Big Pharma Partner to Support R&D https://www.excedr.com/blog/how-biotech-partnerships-support-research
Spatial Biology https://www.akoyabio.com/why-spatial-biology/
Regulatory and reimbursement impacts in Pharma https://www.ncbi.nlm.nih.gov/books/NBK234312/
Drug approval with FDA
Regulatory and reimbursement impacts in Diagnostics https://www.lighthouselabservices.com/understanding-the-keys-to-diagnostic-reimbursement/
Mergers and acquisitions (M&A) https://www.investopedia.com/terms/m/mergersandacquisitions.asp
The Biotech Startups Podcast is handcrafted by our friends over at: fame.so
76 에피소드
Manage episode 411740915 series 3461709
Jon Chee에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 Jon Chee 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.
Part 2 of 3.
As a podcast listener, you can redeem exclusive discounts with a growing list of biotech vendors and get $500 off your first equipment lease by using promo code “TBSP” on https://www.excedr.com/rewards.
As a podcast listener, you can redeem exclusive discounts with a growing list of biotech vendors and get $500 off your first equipment lease by using promo code “TBSP” on https://www.excedr.com/rewards.
My guest for this week’s episode is Terry Lo, President and CEO of Vizgen. Vizgen is developing and commercializing the next generation of genomics tools to expand on the capabilities of spatially resolved transcriptomics.
Terry is a pioneer in the emerging Spatial Biology market, with a proven track record of driving exceptional growth across global life science organizations, including Bristol-Myers Squibb, Roche, Hologic, and PerkinElmer. In addition to his two decades of experience scaling and building multinational biopharma and diagnostic groups, he is also an expert in developing business strategies for novel, innovative products.
Join us for part 2 of our conversation with Terry, where we talk about his transition from Big Pharma to diagnostics, the challenges of moving into the diagnostics industry, and the contrasts between drug and diagnostic development processes. Terry also discusses his experience at Roche, his time with Akoya Biosciences after PerkinElmer, and his involvement in the M&A process while balancing multiple roles. Please enjoy my conversation with Terry Lo.
Find Our Guest, Terry Lo, at these links:
Find Our Guest, Terry Lo, at these links:
Find Our Host, Jon Chee, at these links:
Timestamps:
00:28 Intro
01:35 Leaving Bristol, joining Cytyc, and transitioning into International Strategy role
03:48 The contrasts between Diagnostics and Big Pharma
05:28 Drug development vs. diagnostics development processes
09:27 Moving to China and adapting to his role change from International Strategy to Managing Director
10:43 Adjusting to life in China with his pregnant wife
13:25 Moving back to the US and joining Roche Molecular in California
15:26 Transitioning to PerkinElmer and Terry’s intro to spatial biology
17:28 The challenges and triumphs in this new field
20:25 The challenges of regulatory agencies and reimbursement in Diagnostics and getting a product through the FDA
24:58 Merging with Akoya Biosciences after PerkinElmer to support Terry’s platform
26:51 Terry’s experience with M&A of Akoya by PerkinElmer, balancing multiple roles
29:13 Outro
Social & Website:
LinkedIn: https://www.linkedin.com/company/excedr/
Youtube: https://www.youtube.com/@excedr
Instagram: https://www.instagram.com/excedr_inc
Twitter: https://twitter.com/ExcedrInc
Facebook: https://www.facebook.com/excedr
TikTok: https://www.tiktok.com/@excedr
Podcast Website: https://www.thebiotechstartupspodcast.com/
Topics Mentioned:
Corporate Business Development https://www.rontar.com/blog/corporate-development-vs-business-development/
International Strategy https://phrase.com/blog/posts/international-strategy/
Diagnostics vs. Pharmaceuticals https://tarikyildirim.com/blog/2019/1/21/pharma-vs-diagnostics
P&L statement https://www.investopedia.com/terms/p/plstatement.asp
Drug development vs. diagnostics development https://www.ncbi.nlm.nih.gov/books/NBK235489/
AI/ML in drug development https://www.fda.gov/science-research/science-and-research-special-topics/artificial-intelligence-and-machine-learning-aiml-drug-development
Protein folding https://en.wikipedia.org/wiki/Protein_folding
Protein therapeutics https://www.nature.com/articles/nrd2399
How Biotech & Big Pharma Partner to Support R&D https://www.excedr.com/blog/how-biotech-partnerships-support-research
Spatial Biology https://www.akoyabio.com/why-spatial-biology/
Regulatory and reimbursement impacts in Pharma https://www.ncbi.nlm.nih.gov/books/NBK234312/
Drug approval with FDA
Regulatory and reimbursement impacts in Diagnostics https://www.lighthouselabservices.com/understanding-the-keys-to-diagnostic-reimbursement/
Mergers and acquisitions (M&A) https://www.investopedia.com/terms/m/mergersandacquisitions.asp
The Biotech Startups Podcast is handcrafted by our friends over at: fame.so
76 에피소드
Alla avsnitt
×플레이어 FM에 오신것을 환영합니다!
플레이어 FM은 웹에서 고품질 팟캐스트를 검색하여 지금 바로 즐길 수 있도록 합니다. 최고의 팟캐스트 앱이며 Android, iPhone 및 웹에서도 작동합니다. 장치 간 구독 동기화를 위해 가입하세요.